 |
 |
GEO help: Mouse over screen elements for information. |
|
Status |
Public on Oct 02, 2023 |
Title |
Stem cell-derived human liver organoids to model the progression of inflammatory and fibrotic injury in non-alcoholic fatty liver disease |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Chronic liver injury promotes fibrosis, which can progress to cirrhosis, a major cause of morbidity and mortality worldwide. Resolving the cell-type-specific transcriptional changes orchestrating this transformation remains challenging. Recent advances in differentiation protocols allow the generation of multi-lineage human liver organoids (HLOs) from human pluripotent stem cells (hPSCs), providing a new model system to study evolving liver injury. We differentiated hPSCs into HLOs and defined optimal 3D culture conditions for liver injury induction. We modeled steatohepatitis through treatment with palmitic acid (PA) and fibrotic injury through treatment with transforming growth factor beta 1 (TGF-β1). For each injury type, we evaluated the development of fibrosis and inflammation by monitoring changes in morphology, gene expression, and histology. We then performed single-cell RNA-sequencing (scRNA-seq) to investigate cell-type diversity in healthy organoids at different time-points and to understand how TGF-β1- and PA-mediated injury affects each cell type. We observed transcriptional response signatures in injured HLOs to be both cell-type- and injury-specific. TGF-β1 treatment expanded hepatic stellate cell (HSC)-like populations and remodeled cell-cycle patterning. Gene set scoring revealed increased fibroblast activity with TGF-β1 treatment, while PA treatment was associated with inflammatory activity. Differential gene expression analysis at the subpopulation level showed induced profibrotic and extracellular matrix-remodeling pathways with TGF-β1 and non-alcoholic fatty liver disease (NAFLD) expression signatures with PA treatment. Evaluation of receptor and ligand expression defined hepatocyte-, cholangiocyte-, and HSC-like cell-cell interactions induced upon TGF-β1 treatment, an effect not observed with PA treatment. Tracing the changes at receptor-ligand pair resolution revealed specific COL1A1-Integrin complex interactions with TGF-β1 treatment and inflammation-specific interactions including CXCR7 and HLA-C with PA treatment. Treatment of HLOs with PA and TGF-β1 also demonstrated a sequential increase in expression of gene sets that predict clinical disease progression in non-alcoholic steatohepatitis (NASH). Our results demonstrate the applicability of hPSC-derived HLOs as a dynamic in vitro 3D human liver model system for the study of fibrotic and inflammatory liver injury.
|
|
|
Overall design |
hPSC-derived HLOs cultured on an orbital shaker (OS) were stimulated with TGF-β1 (10 ng/ml) or PA (500 µM) for five days and subjected to scRNAseq at day 25. Additionally, naive (untreated) HLOs cultured on ultra-low attachment (ULA) plates were analyzed by scRNAseq at day 21 and day 34 of the differentiation protocol.
|
|
|
Contributor(s) |
Hess A, Gentile SD, Rahman RU, Mullen AC |
Citation(s) |
37962490 |
|
Submission date |
Jul 11, 2022 |
Last update date |
Jan 02, 2024 |
Contact name |
Alan C. Mullen |
E-mail(s) |
mullenlabmgh@gmail.com
|
Organization name |
Massachusetts General Hospital
|
Department |
Department of Medicine
|
Street address |
55 Fruit St.
|
City |
Boston |
State/province |
MA |
ZIP/Postal code |
02135 |
Country |
USA |
|
|
Platforms (2) |
GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
GPL30173 |
NextSeq 2000 (Homo sapiens) |
|
Samples (19)
|
GSM6322571 |
Day 34 ULA-HLOs, replicate 1, scRNAseq |
GSM6322572 |
Day 34 ULA-HLOs, replicate 2, scRNAseq |
GSM6322573 |
Control-for-TGFB1 day 25 OS-HLOs, replicate 1, scRNAseq |
GSM6322574 |
Control-for-TGFB1 day 25 OS-HLOs, replicate 2, scRNAseq |
GSM6322575 |
TGFB1-10ng/ml treated day 25 OS-HLOs, replicate 1, scRNAseq |
GSM6322576 |
TGFB1-10ng/ml treated day 25 OS-HLOs, replicate 2, scRNAseq |
GSM6322577 |
Control-for-PA day 25 OS-HLOs, replicate 1, scRNAseq |
GSM6322578 |
Control-for-PA day 25 OS-HLOs, replicate 2, scRNAseq |
GSM6322579 |
PA-500 µM treated day 25 OS-HLOs, replicate 1, scRNAseq |
GSM6322580 |
PA-500 µM treated day 25 OS-HLOs, replicate 2, scRNAseq |
GSM6900332 |
Day 25 OS-HLOs, replicate 1, scRNAseq |
GSM6900333 |
Day 25 OS-HLOs, replicate 2, scRNAseq |
GSM6900334 |
Control-for-OA day 25 OS-HLOs, replicate 1, scRNAseq |
GSM6900335 |
Control-for-OA day 25 OS-HLOs, replicate 2, scRNAseq |
GSM6900336 |
OA-500 µM treated day 25 OS-HLOs, replicate 1, scRNAseq |
GSM6900337 |
OA-500 µM treated day 25 OS-HLOs, replicate 2, scRNAseq |
|
Relations |
BioProject |
PRJNA857590 |
Supplementary file |
Size |
Download |
File type/resource |
GSE207889_GEO_supplementary_files.xlsx |
9.1 Kb |
(ftp)(http) |
XLSX |
GSE207889_RAW.tar |
1.1 Gb |
(http)(custom) |
TAR (of MTX, TSV) |
GSE207889_day21.h5ad.gz |
184.2 Mb |
(ftp)(http) |
H5AD |
GSE207889_masld-hlos_merged.h5ad.gz |
613.9 Mb |
(ftp)(http) |
H5AD |
GSE207889_os.h5ad.gz |
652.5 Mb |
(ftp)(http) |
H5AD |
SRA Run Selector |
Raw data are available in SRA |
Processed data provided as supplementary file |
|
|
|
|
 |